| Sartorius | 179.50 / 0.00% |
| Date/Time | 12/09 / 22:00 |
| Chg. / Chg.(%) | 0.00 / 0.00% |
| Bid | 198.00 / 120 |
| Ask | 202.40 / 120 |
| Open | 179.50 |
| Previous Close | 179.50 |
| High | 179.50 |
| Low | 179.50 |
| Volume [CHF] | - |
| Volume [Units] | |
| Price fixings | 1 |
| ISIN | DE0007165631 |
| Security | SRT3 |
| Exchange | SIX Swiss Exchange |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Xetra | 193.10 |  |
35,033 |
| Cboe Europe .. | 192.60 | |
7,367 |
| London Inter.. | 191.45 | |
5,443 |
| Cboe Europe .. | 192.60 | |
4,134 |
| Turquoise | 192.40 | |
3,395 |
| TradeGate | 192.400 | |
2,372 |
| Frankfurt | 193.8000 |  |
821 |
| Stuttgart | 192.800 | |
230 |
| Berlin | 191.60 | |
40 |
| gettex | 193.300 | |
20 |
| Vienna Globa.. | 192.70 | |
0 |
| München | 191.70 | |
0 |
| Hamburg | 191.90 | |
0 |
| Hannover | 191.90 | |
0 |
| Düsseldorf | 191.90 | |
0 |
| SIX Swiss Ex.. | 179.50 | |
|
| Lang & Schwa.. | 192.700 | |
|
| Nasdaq Other.. | 213.5000 | 120 | |
| EUREX | Options | ||
News
- XBiotech Announces Rapid Enrollment for its Randomized Multi-Center Clinical Study for Bermekimab in Patients with Hidradenitis Suppurativa
11/19/2019 / 14:55 - GlobeNewswire - Worldwide Cell Based Assay & High Content Screening Market Forecasts to 2024 - Candidate Growth, Immuno-oncology, Genomic Blizzard, Technology Convergence, The Insurance Effect
10/29/2019 / 11:55 - GlobeNewswire - XBiotech Announces First Patient Enrolled in Randomized Multi-Center Clinical Study Evaluating Bermekimab Therapy in Patients with Hidradenitis Suppurativa
10/23/2019 / 14:15 - GlobeNewswire - Global $1.78Bn Fermenters Market Outlook, 2025
10/23/2019 / 11:26 - GlobeNewswire - 2019 Report on Cell Harvesting: Market Projected to Grow by $157.2M During 2019-2025
10/22/2019 / 18:05 - GlobeNewswire
Real-time